Eli Lilly's Q4 2025 Financial Highlights
Eli Lilly and Company (NYSE: LLY) announced significant growth in its financial performance for the fourth quarter of 2025. The company reported a remarkable 43% increase in revenue, reaching $19.3 billion, primarily driven by strong volume growth from its popular products, Mounjaro and Zepbound.
In addition to revenue growth, Eli Lilly's earnings per share (EPS) rose notably, increasing by 51% to $7.39 on a reported basis. When excluding certain expenses, the non-GAAP EPS grew by 42% to $7.54, which included charges from acquired in-process research and development (IPR&D).
Product Performance and Regulatory Approvals
Eli Lilly made significant strides in regulatory approvals, achieving the U.S. FDA's endorsement for its Kwikpen device catering to tirzepatide and an expanded indication for Jaypirca. The company has also submitted applications for its medication orforglipron for obesity treatment in various international markets.
Key Products Driving Revenue Growth
The company identified its Key Products, which encompass Ebglyss, Inluriyo (effective Q4 2025), Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound, continuing to showcase their contribution towards revenue. Mounjaro alone accounted for $7.4 billion in sales, reflecting a staggering 110% increase year-over-year, making it one of the top revenue generators.
Continued Investments in R&D
Eli Lilly reaffirmed its commitment to innovation, increasing research and development expenditures by 26% to $3.8 billion. This investment underscores the company’s dedication to developing new therapies that address some of the world's most pressing health challenges, such as diabetes and obesity.
On the international front, the revenue outside the U.S. also saw a healthy rise of 43%, amounting to $6.4 billion, driven by an increase in volume and favorable foreign exchange impacts. The global volume growth was mainly propelled by Mounjaro, supplemented by a recovery in Jardiance sales following a previously noted adjustment.
Looking Ahead: 2026 Financial Guidance
As Eli Lilly assesses its future, the company has laid out ambitious guidance for 2026. The projected revenue range is between $80 billion and $83 billion, with a non-GAAP EPS set between $33.50 to $35.00. This guidance illustrates Eli Lilly's optimism and strategic approach to capitalizing on market opportunities, ensuring that it continues to make life better for more patients globally.
Summary of Financial Performance
The company also discussed its profitability metrics, indicating a gross margin of 82.5%. This figure represents a slight increase compared to previous quarters, attributed to a favorable product mix and improved production costs, despite pressures from lower realized prices.
Investment in Future Growth
Beyond just financial performance, Eli Lilly is dedicated to expanding access to its obesity medicines, as evidenced by their recent agreements with the U.S. government. Such initiatives aim to ensure that millions more patients can benefit from effective treatments.
Frequently Asked Questions
What are Eli Lilly's revenue growth figures for Q4 2025?
Eli Lilly reported a remarkable 43% increase in revenue, amounting to $19.3 billion.
What is the projected revenue for Eli Lilly in 2026?
The company projects its revenue to be between $80 billion to $83 billion for 2026.
How did the EPS change from Q4 2024 to Q4 2025?
Eli Lilly's EPS increased by 51% from $4.88 in Q4 2024 to $7.39 in Q4 2025.
What significant regulatory steps has Eli Lilly taken recently?
Recent regulatory approvals include the FDA's endorsement of Kwikpen for tirzepatide and expanded indications for Jaypirca.
What investments is Eli Lilly making in research and development?
Eli Lilly has increased its R&D spending by 26%, investing $3.8 billion to support the development of new therapies.
